therapeut
effect
postexposur
treatment
antiserum
sever
fever
thrombocytopenia
syndrom
sft
mous
model
sft
viru
infect
introduct
sever
fever
thrombocytopenia
syndrom
sft
emerg
diseas
first
report
rural
area
central
china
yu
et
al
sft
current
identifi
korea
japan
kim
et
al
takahashi
et
al
date
case
confirm
china
case
mortal
rang
liu
et
al
liu
et
al
japan
specif
western
part
total
case
death
identifi
year
yamaguchi
prefectur
surveil
center
infecti
diseas
earliest
case
among
report
sft
case
worldwid
patient
nagasaki
infect
caus
agent
sft
viru
sftsv
belong
genu
phleboviru
famili
buniyavirida
yu
et
al
sftsv
transmit
human
bite
infect
tick
humantohumantransmiss
occur
contact
blood
infect
person
liu
et
al
tang
et
al
wang
et
al
may
mucou
membran
skin
wound
healthi
person
clinic
manifest
sft
fever
headach
fatigu
myalgia
gastrointestin
symptom
vomit
diarrhea
thrombocytopenia
leukopenia
fatal
rate
rang
percent
liu
et
al
liu
et
al
takahashi
et
al
yu
et
al
although
detail
mechan
sever
diseas
fulli
understood
report
viral
copi
number
blood
serum
fatal
case
significantli
higher
surviv
outcom
gai
et
al
yoshikawa
et
al
thu
suppress
viral
replic
patient
import
option
therapeut
treatment
fatal
form
diseas
china
ribavirin
prescrib
sft
patient
attempt
treat
oh
et
al
japan
clinician
tri
treat
sever
sft
patient
steroid
methylprednisolon
treatment
hemophagocyt
syndrom
iasr
howev
effect
vivo
unclear
effect
vaccin
specif
treatment
sft
current
avail
inject
antiserum
blood
transfus
patient
attempt
treat
viral
diseas
name
ebola
hemorrhag
fever
sar
coronaviru
rabi
tickborn
enceph
broker
kollaritsch
khawplod
et
al
mairjenkin
et
al
mupapa
et
al
antivir
agent
nucleotid
analog
proteas
inhibitor
may
also
candid
therapeut
treatment
sft
ribavirin
guanosin
analog
shown
effect
treatment
viral
diseas
keshtkarjahromi
et
al
lang
et
al
mccormick
et
al
sidwel
barnard
cellular
proteas
subtilisin
kexin
proteas
inhibitor
shown
antivir
activ
rna
virus
olmstead
et
al
pasquato
et
al
urata
et
al
vitro
experi
suggest
suppress
effect
sftsv
propag
cultur
cell
unpublish
data
rais
possibl
antivir
effect
japan
endem
area
sft
overlap
region
japanes
spot
fever
caus
agent
rickettsia
japonica
agent
also
transmit
tick
mahara
area
febril
patient
tick
bite
suspect
spot
fever
gener
treat
antibiot
minocyclin
mino
ciprofloxacin
cpfx
earli
phase
diseas
howev
known
whether
antibiot
treat
exacerb
sft
infect
elucid
pathogenesi
sftsv
infect
vivo
laboratori
mous
model
balbc
kunm
strain
use
jin
et
al
howev
adult
mice
strain
exhibit
appar
clinic
sign
mice
fatal
outcom
indic
immunocompet
adult
mice
suscept
sftsv
hand
alpha
beta
interferon
receptor
knockout
ifnar
mice
highli
suscept
sftsv
infect
adult
mice
report
die
follow
subcutan
inocul
focusform
unit
ffu
sftsv
liu
et
al
thu
ifnar
mice
regard
use
anim
sftsv
infect
model
vivo
studi
investig
effect
ribavirin
steroid
human
antiserum
sftsv
infect
use
ifnar
mous
model
furthermor
also
examin
effect
mino
cpfx
mous
model
follow
sftsv
infect
examin
pathogen
strain
sftsv
observ
clinic
sign
mice
strain
background
ifnar
ko
mice
subcutan
inocul
high
ffu
low
ffu
dose
sftsv
high
doseinfect
mice
develop
acut
clinic
sign
includ
piloerect
slow
movement
anorexia
sever
weight
loss
day
postinfect
pi
die
day
pi
fig
hand
low
doseinfect
mice
exhibit
weight
reduct
day
pi
recov
day
pi
fig
b
viral
load
spleen
high
doseinfect
mice
significantli
higher
low
doseinfect
mice
day
pi
fig
observ
indic
high
low
dose
infect
mice
repres
lethal
nonleth
model
sftsv
infect
respect
next
examin
therapeut
effect
ribavirin
steroid
antiserum
mice
infect
high
low
dose
sftsv
fig
antiserum
collect
recov
sft
human
case
serum
neutral
antibodi
titer
measur
focu
reduct
neutral
follow
lethal
infect
sftsv
group
mice
acut
weight
reduct
similar
salin
mock
treat
mice
fig
steroidtr
mice
die
one
five
mice
surviv
ribavirin
treatment
fig
c
mice
surviv
treatment
antiserum
although
weight
reduct
similar
mocktreat
mice
day
pi
fig
c
follow
nonleth
infect
sftsv
mock
ribavirin
steroidtr
mice
show
weight
reduct
fig
although
mock
steroidtr
mice
weight
reduct
three
five
ribavirintr
mice
show
slight
less
decreas
weight
fig
antiserumtr
mice
howev
exhibit
signific
weight
reduct
clinic
sign
fig
result
suggest
antiserum
sft
patient
potenti
therapeut
effect
lethal
nonleth
sftsv
infect
vivo
although
ribavirin
statist
signific
effect
show
slight
protect
effect
lethal
nonleth
infect
steroid
treatment
show
appar
therapeut
benefit
sft
infect
howev
seem
add
detriment
effect
progress
diseas
mice
antiserum
exhibit
signific
protect
fatal
infect
sftsv
thu
compar
viral
load
mice
infect
lethal
dose
sftsv
treatment
antiserum
mock
salin
day
pi
copi
number
viral
rna
lung
spleen
liver
kidney
brain
spinal
cord
significantli
differ
mockand
antiserumtr
group
fig
howev
day
pi
level
spleen
kidney
brain
antiserumtr
mice
significantli
lower
mocktreat
mice
fig
although
differ
tissu
signific
level
lung
liver
tend
lower
antiserumtr
mice
mocktreat
mice
day
pi
fig
thu
seem
mice
treat
antiserum
suppress
level
viral
replic
howev
evid
requir
show
antiserum
realli
effect
viru
replic
help
rescu
mice
lethal
infect
mechan
may
contribut
rescu
mice
lethal
infect
sftsv
next
examin
time
effect
treatment
antiserum
sftsv
infect
mice
fig
antiserum
treatment
start
h
h
lethal
doseinfect
mice
show
surviv
rate
respect
fig
weight
reduct
group
similar
control
group
fig
surviv
rate
weight
chang
nonlethalinfect
mice
significantli
differ
among
three
group
h
h
control
fig
observ
suggest
earli
treatment
antiserum
import
signific
effect
sftsv
infect
next
investig
effect
mino
cpfx
sftsv
infect
mice
follow
lethal
dose
infect
fig
although
mice
die
surviv
time
minocyclin
ciprofloxacin
mc
treat
mice
slightli
longer
mocktreat
mice
fig
weight
chang
significantli
differ
fig
viral
load
spleen
liver
brain
cortex
day
pi
significantli
differ
mcand
mocktreat
group
fig
therefor
mctreatment
may
influenc
lessen
sever
sftsv
infect
rout
simpl
suppress
viral
replic
mice
viral
load
tissu
salineand
antiserumtr
mice
follow
infect
ffu
sftsv
copi
number
lung
spleen
liver
kidney
brain
cortex
noncortex
spinal
cord
mice
day
determin
rtpcr
p
mann
whitney
test
studi
show
vivo
mous
model
postexposur
prophylaxi
sft
human
antiserum
complet
protect
mice
lethal
infect
sftsv
treatment
also
protect
mice
clinic
sign
infect
nonleth
dose
sftsv
suggest
antiserum
treatment
clinic
use
postexposur
prophylaxi
sftsv
infect
result
show
earli
treatment
antiserum
requir
effici
recoveri
diseas
shown
mous
model
howev
natur
infect
sftsv
tick
bite
difficult
antiserum
treatment
soon
infect
hand
sftsv
infect
direct
contact
infect
blood
bloodi
secret
tang
et
al
thu
antiserum
treatment
like
use
individu
hospit
healthcar
worker
rel
patient
may
hospitalacquir
infect
antiserum
use
studi
show
high
neutral
antibodi
titer
treatment
serum
result
suppress
effect
sftsv
replic
vivo
inoculum
dilut
serum
per
mous
inject
four
time
everi
h
howev
would
difficult
prepar
inject
scale
inoculum
volum
human
case
thu
improv
product
effici
abund
amount
antivir
antibodi
high
neutral
activ
need
provid
practic
strategi
treatment
sft
altern
use
pool
antisera
could
also
provid
practic
clinic
sourc
report
ribavirin
effect
rna
viru
infect
hepat
c
viru
lang
et
al
lassa
fever
viru
mccormick
et
al
crimeancongo
hemorrhag
fever
viru
keshtkarjahromi
et
al
respiratori
syncyti
viru
sidwel
barnard
practic
combin
antivir
therapi
ribavirin
interferon
agent
sofosbuvir
use
standard
treatment
hepat
c
dhingra
et
al
inhibitori
effect
ribavirin
sftsv
replic
recent
shown
vitro
assay
studi
slight
protect
effect
observ
ribavirin
treatment
although
differ
statist
signific
therefor
combin
ribavirin
antivir
agent
may
possibl
effect
treatment
diseas
mc
treatment
result
prolong
surviv
time
mice
compar
nontreat
mice
follow
lethal
infect
sftsv
howev
viral
load
tissu
significantli
differ
mcand
mocktreat
group
thu
unknown
mechan
mino
cpfx
may
contribut
prolong
surviv
effect
noteworthi
mc
treatment
unlik
exacerb
diseas
cours
due
sftsv
infect
thu
mc
treatment
consid
suspect
case
spot
fever
caus
rickettsia
japonica
endem
area
japan
even
though
diagnosi
spot
fever
sft
definit
anim
model
sftsv
infect
immunocompet
mice
hamster
studi
adult
anim
show
appar
diseas
jin
et
al
liu
et
al
liu
et
al
show
ifnar
mice
highli
suscept
sftsv
infect
liu
et
al
studi
use
ifnar
mice
background
strain
report
previous
liu
et
al
use
differ
viru
strain
japanes
isol
strain
viru
challeng
previou
studi
show
fatal
infect
ffu
sftsv
also
show
ffu
sftsv
strain
caus
lethal
infect
furthermor
show
inocul
ffu
sftsv
caus
nonleth
infect
nonleth
infect
induc
clinic
sign
includ
weight
reduct
mice
surviv
human
case
suggest
patient
viral
load
relat
diseas
sever
gai
et
al
yoshikawa
et
al
thu
comparison
differ
infect
dose
may
provid
promis
approach
elucid
mechan
sft
sever
furthermor
dosedepend
mous
model
sftsv
infect
need
evalu
futur
antivir
drug
postexposur
prophylaxi
sftsv
infect
studi
show
postexposur
prophylaxi
human
antiserum
sft
patient
signific
therapeut
effect
sftsv
infect
vivo
mous
model
result
strongli
suggest
antiserum
treatment
may
clinic
use
postexposur
prophylaxi
sftsv
infect
strain
sftsv
kindli
provid
ken
maeda
yamaguchi
univers
stock
viru
sftsv
prepar
cell
cultur
medium
vero
cell
vero
cell
maintain
eagl
minim
essenti
medium
emem
nissui
pharmaceut
co
contain
fetal
bovin
serum
fb
experi
use
live
sftsv
perform
biosafeti
level
laboratori
nagasaki
univers
accord
standard
guidelin
serum
collect
patient
contract
diseas
collect
done
eight
year
recoveri
patient
control
serum
collect
healthi
volunt
infect
sftsv
experi
use
human
serum
perform
approv
ethic
committe
institut
tropic
medicin
nagasaki
univers
approv
number
sftsv
titer
determin
focu
form
assay
confluent
vero
cell
inocul
serial
dilut
cultur
supernat
sftsv
stock
incub
fc
emem
contain
methyl
cellulos
wako
pure
chemic
industri
ltd
day
viral
foci
detect
use
sftsv
antiserum
peroxidaseconjug
antihuman
igg
american
qualex
dab
substrat
wako
pure
chemic
industri
ltd
viral
titer
express
ffuml
neutral
antibodi
titer
antiserum
determin
focusreduct
assay
serial
dilut
sera
mix
sftsv
incub
h
vero
cell
inocul
mixtur
incub
day
focu
stain
perform
describ
neutral
titer
determin
reciproc
highest
serum
dilut
reduc
viral
foci
count
mice
purchas
b
k
univers
limit
mice
mate
facil
nagasaki
univers
adult
older
eightweekold
mice
subcutan
inocul
ffu
sftsv
dilut
emem
contain
fb
mice
weigh
daili
observ
clinic
signsth
experiment
protocol
approv
anim
care
use
committe
nagasaki
univers
approv
number
ribavirin
wako
pure
chemic
industri
ltd
adooq
bioscienc
steroid
methylprednisolon
sodium
succin
sawai
pharmaceut
co
ltd
dilut
salin
diluent
intraperiton
administ
mice
mg
mg
mg
per
mous
respect
h
follow
infect
sftsv
fig
mino
minomycin
pfizer
japan
inc
cpfx
nichiiko
pharmaceut
co
ltd
dilut
salin
mixtur
intraperiton
inject
mg
antibiot
per
mous
h
inocul
sftsv
fig
sera
dilut
tenfold
salin
diluent
intraperiton
inject
h
inocul
sftsv
fig
salin
diluent
control
serum
volum
drug
antiserum
use
mock
treatment
one
four
day
pi
three
five
mice
sacrif
lung
spleen
liver
kidney
brain
spinal
cord
collect
follow
perfus
cold
phosphatebuff
salin
brain
divid
two
fraction
cortex
noncortex
tissu
immedi
submerg
rnalat
ambion
store
use
total
rna
extract
use
rneasi
lipid
tissu
mini
kit
qiagen
viral
copi
number
examin
realtim
rtpcr
sftsvspecif
primer
probe
design
base
rdrp
region
consensu
sequenc
l
segment
forward
primer
revers
primer
primetim
qpcr
probe
ibfq
integr
dna
technolog
realtim
rtpcr
reaction
perform
use
one
step
primescript
rtpcr
kit
takara
bio
inc
realtim
rtpcr
system
appli
biosystem
copi
number
calcul
ratio
copi
number
standard
control
gehanbreslowwilcoxon
test
perform
assess
surviv
curv
sftsvinfect
group
mice
mann
whitney
test
use
assess
signific
differ
viral
rna
level
